PubMed:23297506 JSONTXT

{"project":"Allie","denotations":[{"id":"SS1_23297506_2_0","span":{"begin":155,"end":178},"obj":"expanded"},{"id":"SS2_23297506_2_0","span":{"begin":180,"end":183},"obj":"abbr"},{"id":"SS1_23297506_2_1","span":{"begin":230,"end":250},"obj":"expanded"},{"id":"SS2_23297506_2_1","span":{"begin":252,"end":254},"obj":"abbr"}],"relations":[{"id":"AE1_23297506_2_0","pred":"abbreviatedTo","subj":"SS1_23297506_2_0","obj":"SS2_23297506_2_0"},{"id":"AE1_23297506_2_1","pred":"abbreviatedTo","subj":"SS1_23297506_2_1","obj":"SS2_23297506_2_1"}],"text":"[Efficacy of compound Xuanju capsule in the treatment of chronic prostatitis with erectile dysfunction].\nOBJECTIVE: To evaluate the efficacy and safety of Compound Xuanju Capsule (CXC) in the treatment of chronic prostatitis with erectile dysfunction (ED).\nMETHODS: We obtained NIH-CPSI and IIEF-5 scores from 132 chronic prostatitis patients with ED and divided the patients into a control (n = 70) and a treatment group (n = 62), the former treated with oral levofloxacin 0.2 g bid for 4-6 weeks and oral Terazosin at 2 mg qd for 2 months, and the latter with oral CXC once 2 capsules tid for 2 months in addition to the above.\nRESULTS: None of the patients had serious medication-related adverse reactions. After treatment, the control group showed significantly decreased NIH-CPSI scores and slightly increased IIEF-5 scores as compared with the baseline (16.5 +/- 5.9 vs 25.1 +/- 5.5, P \u003c 0.05 and 13.1 +/- 5.2 vs 11.3 +/- 4.5, P \u003e 0.05), while the treatment group exhibited significant improvement in both NIH-CPSI (13.4 +/- 5.7 vs 25.5 +/- 5.3, P \u003c 0.05) and IIEF-5 scores (17.5 +/- 6.5 vs 10.8 +/- 3.8, P \u003c 0.05). The total effectiveness rate for ED was significantly higher in the treatment than in the control group (74.2% vs 20%, P \u003c 0.05).\nCONCLUSION: Compound Xuanju Capsule can significantly alleviate both the symptoms of chronic prostatitis and ED in the treatment of chronic prostatitis patients with ED."}

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":230,"end":250},"obj":"HP_0000802"}],"text":"[Efficacy of compound Xuanju capsule in the treatment of chronic prostatitis with erectile dysfunction].\nOBJECTIVE: To evaluate the efficacy and safety of Compound Xuanju Capsule (CXC) in the treatment of chronic prostatitis with erectile dysfunction (ED).\nMETHODS: We obtained NIH-CPSI and IIEF-5 scores from 132 chronic prostatitis patients with ED and divided the patients into a control (n = 70) and a treatment group (n = 62), the former treated with oral levofloxacin 0.2 g bid for 4-6 weeks and oral Terazosin at 2 mg qd for 2 months, and the latter with oral CXC once 2 capsules tid for 2 months in addition to the above.\nRESULTS: None of the patients had serious medication-related adverse reactions. After treatment, the control group showed significantly decreased NIH-CPSI scores and slightly increased IIEF-5 scores as compared with the baseline (16.5 +/- 5.9 vs 25.1 +/- 5.5, P \u003c 0.05 and 13.1 +/- 5.2 vs 11.3 +/- 4.5, P \u003e 0.05), while the treatment group exhibited significant improvement in both NIH-CPSI (13.4 +/- 5.7 vs 25.5 +/- 5.3, P \u003c 0.05) and IIEF-5 scores (17.5 +/- 6.5 vs 10.8 +/- 3.8, P \u003c 0.05). The total effectiveness rate for ED was significantly higher in the treatment than in the control group (74.2% vs 20%, P \u003c 0.05).\nCONCLUSION: Compound Xuanju Capsule can significantly alleviate both the symptoms of chronic prostatitis and ED in the treatment of chronic prostatitis patients with ED."}